-+ 0.00%
-+ 0.00%
-+ 0.00%

Purple Biotech says IM1240 tri-specific antibody shows potent activity in resistant tumor samples

PUBT·05/15/2026 11:01:06
Listen to the news
Purple Biotech says IM1240 tri-specific antibody shows potent activity in resistant tumor samples
  • Purple Biotech highlighted new preclinical data for IM1240, a tri-specific antibody program, showing anti-tumor activity in treatment-resistant patient-derived tumor samples.
  • Disclosure did not indicate results were previously presented or scheduled for a future presentation.
  • Readout supports continued development of IM1240, reinforcing pipeline optionality in hard-to-treat cancers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Purple Biotech Ltd. published the original content used to generate this news brief on May 15, 2026, and is solely responsible for the information contained therein.